Quantum Genomics
Focus: Quantum Genomics is a Paris-based biotechnology company focused on small molecule development in neurology and respiratory therapeutic areas. The company operates a dual portfolio of generic/ANDA products and early-stage pipeline programs.
Profile data last refreshed 2h ago · AI intelligence enriched 1mo ago
Open Jobs
9+9 this month
Growing — net +9 jobs in 30d
13 jobs added vs 4 removed. Steady team buildout.
Should You Work at Quantum Genomics?
AI assessmentQuantum Genomics presents a clinical upside thesis around Phase 3 hypertension asset but carries material visibility and operational risk due to opaque financials, no current hiring, and generic-dominated revenue model.
Why Work Here
- Lead a Phase 3 program (Firibastat for hypertension) with near-term regulatory catalysts and clinical validation
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1M Part DStable
Pre-Launch
Lead revenue driver (54% of portfolio) but pre-launch status and modest Part D spend suggest early commercialization phase.
Help build intelligence for Quantum Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.